Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy

Peter J Dyck, P. C. O'Brien

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Use of nerve conduction in assessing therapy in preventing or ameliorating neuropathy is desirable because abnormalities of nerve conduction are associated with severity of neuropathic symptoms and deficits. Assuming that a therapy is associated with a statistically significant improvement of nerve conduction, what degree of nerve conduction change is clinically meaningful? We suggest that in controlled clinical trials, a mean change of 2 points on the neurologic disability score is clinically detectable and meaningful. Based on our previously published cross-sectional epidemiological data, this corresponds to a change of motor nerve conduction velocity of the average ulnar median and peroneal nerves of 2.9 m/s and peroneal nerve of 2.2 m/s. The corresponding changes of amplitude were 1.2 and 0.7 mV, respectively. Smaller degrees of nerve conduction changes were found when only insulin-dependent patients were evaluated.

Original languageEnglish (US)
Pages (from-to)649-652
Number of pages4
JournalDiabetes Care
Volume12
Issue number9
StatePublished - 1989

Fingerprint

Diabetic Neuropathies
Neural Conduction
Controlled Clinical Trials
Peroneal Nerve
Ulnar Nerve
Median Nerve
Nervous System
Insulin
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. / Dyck, Peter J; O'Brien, P. C.

In: Diabetes Care, Vol. 12, No. 9, 1989, p. 649-652.

Research output: Contribution to journalArticle

@article{66b0bef8664544868a54f5ee8ffa26dc,
title = "Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy",
abstract = "Use of nerve conduction in assessing therapy in preventing or ameliorating neuropathy is desirable because abnormalities of nerve conduction are associated with severity of neuropathic symptoms and deficits. Assuming that a therapy is associated with a statistically significant improvement of nerve conduction, what degree of nerve conduction change is clinically meaningful? We suggest that in controlled clinical trials, a mean change of 2 points on the neurologic disability score is clinically detectable and meaningful. Based on our previously published cross-sectional epidemiological data, this corresponds to a change of motor nerve conduction velocity of the average ulnar median and peroneal nerves of 2.9 m/s and peroneal nerve of 2.2 m/s. The corresponding changes of amplitude were 1.2 and 0.7 mV, respectively. Smaller degrees of nerve conduction changes were found when only insulin-dependent patients were evaluated.",
author = "Dyck, {Peter J} and O'Brien, {P. C.}",
year = "1989",
language = "English (US)",
volume = "12",
pages = "649--652",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy

AU - Dyck, Peter J

AU - O'Brien, P. C.

PY - 1989

Y1 - 1989

N2 - Use of nerve conduction in assessing therapy in preventing or ameliorating neuropathy is desirable because abnormalities of nerve conduction are associated with severity of neuropathic symptoms and deficits. Assuming that a therapy is associated with a statistically significant improvement of nerve conduction, what degree of nerve conduction change is clinically meaningful? We suggest that in controlled clinical trials, a mean change of 2 points on the neurologic disability score is clinically detectable and meaningful. Based on our previously published cross-sectional epidemiological data, this corresponds to a change of motor nerve conduction velocity of the average ulnar median and peroneal nerves of 2.9 m/s and peroneal nerve of 2.2 m/s. The corresponding changes of amplitude were 1.2 and 0.7 mV, respectively. Smaller degrees of nerve conduction changes were found when only insulin-dependent patients were evaluated.

AB - Use of nerve conduction in assessing therapy in preventing or ameliorating neuropathy is desirable because abnormalities of nerve conduction are associated with severity of neuropathic symptoms and deficits. Assuming that a therapy is associated with a statistically significant improvement of nerve conduction, what degree of nerve conduction change is clinically meaningful? We suggest that in controlled clinical trials, a mean change of 2 points on the neurologic disability score is clinically detectable and meaningful. Based on our previously published cross-sectional epidemiological data, this corresponds to a change of motor nerve conduction velocity of the average ulnar median and peroneal nerves of 2.9 m/s and peroneal nerve of 2.2 m/s. The corresponding changes of amplitude were 1.2 and 0.7 mV, respectively. Smaller degrees of nerve conduction changes were found when only insulin-dependent patients were evaluated.

UR - http://www.scopus.com/inward/record.url?scp=0024458030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024458030&partnerID=8YFLogxK

M3 - Article

C2 - 2676432

AN - SCOPUS:0024458030

VL - 12

SP - 649

EP - 652

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -